Idiopathic Fibrosis: The Role of Biomarkers

Daniel Kurbanov, MD
Clinical Fellow of Pulmonary Medicine
Yale School of Medicine

Wednesday, September 25, 2019, 3-4 pm
Fitkin Amphitheatre

Moderator: Richard Matthay, MD

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

NEEDS ASSESSMENT
The understanding of idiopathic fibrosis (IPF) continues to develop. Genetic studies have revealed strong associations with gene variants. Gene expression and peripheral blood proteins have been shown to predict outcomes, highlighting disease subphenotypes. These biomarker findings can shed light on the important questions of etiology, risk factors, and outcome prediction – the questions that patients and clinicians have about this disease.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will learn to:
1. Learn about types of biomarkers
2. Understand how biomarkers can help explain idiopathic pulmonary fibrosis
3. Discuss current and future roles of biomarkers in idiopathic pulmonary fibrosis management and research

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Richard Matthay, MD, Course Director – No conflicts of interest
Daniel Kurbanov, MD – No conflicts of interest

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.